TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8427853

Group type: EXPERIMENTAL
Intervention: Weight loss treatment groups
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study: 2887102

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3
Study: 29787858

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling plus nicotine replacement therapy (C + NRT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Smoking cessation counseling (C)
Number of subjects: 278
Study: 27504637

Group type: EXPERIMENTAL
Intervention: Immediate ART offered to all HIV-positive adults
Number of subjects: 12894

Group type: COMPARATOR
Intervention: ART offered according to national guidelines (CD4 count ≤ 350 cells/μl)
Number of subjects: 12894

Group type: EXPERIMENTAL
Intervention: Home-based HIV testing
Number of subjects: 12894

Group type: EXPERIMENTAL
Intervention: Linkage to care within 6 months
Number of subjects: 12894

Group type: EXPERIMENTAL
Intervention: Community attitudes about ART
Number of subjects: 12894

Group type: EXPERIMENTAL
Intervention: Estimated baseline HIV prevalence
Number of subjects: 12894
Study: 25017577

Group type: EXPERIMENTAL
Intervention: Fresh lutein-enriched egg-yolk beverage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dried version of the lutein-enriched egg-yolk beverage
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Beverage composed of the dried individual components
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain control beverage
Number of subjects: 100
Study: 22895351

Group type: EXPERIMENTAL
Intervention: 4 mg/kg/d propranolol for 12 months postburn
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (no propranolol)
Number of subjects: 179
Study: 20683279

Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica montana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17910332

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with Culex quinquefasciatus extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15088866

Group type: EXPERIMENTAL
Intervention: Selection by location
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selection by color
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral letters
Number of subjects: 0
Study: 11574763

Group type: EXPERIMENTAL
Intervention: Mito-FLAG protocol (mitoxantrone 7 mg/m² days 1/3/5, fludarabine 15 mg/m² every 12 h days 1-5, cytarabine as bolus infusion 1000 mg/m² over 1 h every 12 h days 1-5)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mito-FLAG protocol (cytarabine as continuous infusion 100-150 mg/m² over 24 h days 1-5)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mito-FLAG protocol
Number of subjects: 29
Study: 9692704

Group type: EXPERIMENTAL
Intervention: 1-hour topical method (bismuth, metronidazole, amoxycillin, pronase) after a 6-week course of ranitidine and omeprazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amoxycillin (2 g/day) plus omeprazole (20 mg b.d.) for 2 weeks followed by a 4-week course of ranitidine
Number of subjects: 80
Study: 7933682

Group type: EXPERIMENTAL
Intervention: ATP infusion at 0.16 mg/kg/min (group A)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: ATP infusion at 0.18 mg/kg/min (group B)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Overall (combined groups)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Side effects from ATP infusion
Number of subjects: 172
Study: 2965719

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mequitazine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 31987724

Group type: COMPARATOR
Intervention: Control group from the Community Youth Development Study
Number of subjects: 2002
Study: 29741564

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (36:9:19:4; n = 62)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: n-6 PUFA-rich diet (36:9:13:10; n = 66)
Number of subjects: 190

Group type: COMPARATOR
Intervention: SFA-rich diet (36:17:11:4; n = 64)
Number of subjects: 190
Study: 27449150

Group type: EXPERIMENTAL
Intervention: High-fidelity simulator
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Real patients (post-simulation practice)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Post-simulation assessment scores
Number of subjects: 52
Study: 24679061

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg per day)
Number of subjects: 10010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10010
Study: 22642525

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive‐behavioral treatment (Unified Protocol for the Treatment of Emotional Disorders in Youth)
Number of subjects: 31
Study: 20856132

Group type: EXPERIMENTAL
Intervention: Behavioral feedback intervention (nurse-delivered adherence intervention)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Behavioral feedback intervention
Number of subjects: 15
Study: 18072016

Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: simvastatin (40 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: combination of ezetimibe and simvastatin
Number of subjects: 72
Study: 16579717

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for insomnia
Number of subjects: 209

Group type: COMPARATOR
Intervention: Primary care reference values
Number of subjects: 209
Study: 15598784

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.5 mug/kg weekly for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 11700903

Group type: EXPERIMENTAL
Intervention: Syllable number/grammatical category relationship matched English
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syllable number/grammatical category relationship opposite to English
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No relationship between syllable number and grammatical category
Number of subjects: 0
Study: 9270645

Group type: EXPERIMENTAL
Intervention: Minimal-dose aprotinin (1.0 x 10(6) KIU)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (2.7 +/- 0.5 x 10(6) KIU)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (no aprotinin treatment)
Number of subjects: 167
Study: 8173929

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 849

Group type: COMPARATOR
Intervention: Non-irradiated patients
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Both groups (irradiated and non-irradiated)
Number of subjects: 849
Study: 3130221

Group type: EXPERIMENTAL
Intervention: NORPLANT implants
Number of subjects: 240

Group type: COMPARATOR
Intervention: NORPLANT-2 implants
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Both NORPLANT and NORPLANT-2 implants
Number of subjects: 240
Study: 31600749

Group type: EXPERIMENTAL
Intervention: Urinary biomarkers (β2MG and MCP-1)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 302
Study: 28522646

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 39
Study: 25510450

Group type: EXPERIMENTAL
Intervention: Peer network intervention including peer mediation and direct instruction
Number of subjects: 95

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 95
Study: 23694782

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2437
Study: 22111972

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 27
Study: 19471286

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-eluting stents
Number of subjects: 0
Study: 16644323

Group type: EXPERIMENTAL
Intervention: BNP levels < 100 pg/mL
Number of subjects: 601

Group type: COMPARATOR
Intervention: BNP levels >= 100 pg/mL
Number of subjects: 601
Study: 12475575

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (0.4‐0.8 mg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous fenoterol (60 ‐ 120 microg/h)
Number of subjects: 50
Study: 10849527

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (CT) - Cycle 1: cytarabine 200 mg/m2/day (days 1-7) and idarubicin 12 mg/m2/day (days 1-2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (CT) - Cycle 2: cytarabine 2000 mg/m2/day (days 1-6) and amsacrine 120 mg/m2/day (days 1-3)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AutoSCT eligibility after CT
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IFNalpha maintenance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cytogenetic examination of bone marrow
Number of subjects: 19
Study: 9377317

Group type: EXPERIMENTAL
Intervention: ECCE (Extracapsular Cataract Extraction)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ECCE
Number of subjects: 64
Study: 8473644

Group type: COMPARATOR
Intervention: No aspirin for > or = 10 days and no heparin (n = 12)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No aspirin for > or = 10 days but heparin, 10,000 IU, at the time of catheterization (n = 5)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/day, for at least 5 days (n = 11)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aspirin, 75 mg/day for > or = 5 days before angioplasty (n = 11)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/day for > or = 3 days before angioplasty (n = 9)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aspirin, 300 mg/day for > or = 3 days before angioplasty followed by 1,000 mg during angioplasty (n = 9)
Number of subjects: 57
Study: 2951806

Group type: EXPERIMENTAL
Intervention: salbutamol 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: combination of fenoterol 200 micrograms and ipratropium bromide 80 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31663831

Group type: EXPERIMENTAL
Intervention: Direct mechanical thrombectomy (MT)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Combined intravenous thrombolysis plus mechanical thrombectomy (MT)
Number of subjects: 636
Study: 31847977

Group type: EXPERIMENTAL
Intervention: Group A: papain 2% or 4% topical therapy, Unna boot compression therapy in phase 2
Number of subjects: 28

Group type: COMPARATOR
Intervention: Group B: 2% hydrogel topical therapy, cellulose membrane followed by Unna boot compression therapy in phase 2
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups received single-layer elastic compression therapy (SurePress; ConvaTec) and educational activities, exercises, leg elevation, oral nutrition supplementation, and ulcer cleaning
Number of subjects: 28
Study: 27845510

Group type: EXPERIMENTAL
Intervention: Monopolar electrode resection loop (group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bipolar electrode resection loop (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 100
Study: 25515123

Group type: EXPERIMENTAL
Intervention: Electric-acoustic stimulation (EAS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bilateral cochlear implants (CI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal hearing control group
Number of subjects: 22
Study: 23380137

Group type: EXPERIMENTAL
Intervention: PR3‐ANCA levels in relapsing patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PR3‐ANCA levels in non-relapsing patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Increment of PR3‐ANCA from remission to peak in relapsing patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PR3‐ANCA values at entry in relapsing patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Peak PR3‐ANCA values in relapsing patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Median time to reach peak PR3‐ANCA values in relapsing patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Median time to reach peak PR3‐ANCA values in non-relapsing patients
Number of subjects: 28
Study: 21318582

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3252

Group type: COMPARATOR
Intervention: Moderately reduced GFR
Number of subjects: 3252
Study: 20027453

Group type: EXPERIMENTAL
Intervention: 5% NaF varnish (G1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 6% NaF + 6% CaF(2) varnish (G2)
Number of subjects: 15
Study: 17867479

Group type: EXPERIMENTAL
Intervention: 2% Hydroxypropyl Methylcellulose (HPMC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% Sodium Hyaluronate (NaHa)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 14741244

Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise at 60% VO(2peak) after caffeine ingestion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate intensity cycling exercise at 60% VO(2peak) after placebo ingestion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Quiet rest after caffeine ingestion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Quiet rest after placebo ingestion
Number of subjects: 16
Study: 11502917

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days, then 10 mg/day thereafter)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431

Group type: COMPARATOR
Intervention: Donepezil and Placebo
Number of subjects: 431
Study: 9745423

Group type: EXPERIMENTAL
Intervention: GH therapy (starting dose, 10 +/- 0.3 micrograms/kg per day; mean treatment dose, 4 +/- 2 micrograms/kg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8150348

Group type: EXPERIMENTAL
Intervention: Rifampicin, isoniazid, and ethambutol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 3179642

Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA (0.1-0.2 mmol/kg body weight)
Number of subjects: 20
Study: 31986989

Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Alteplase 10 mg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Alteplase (both doses)
Number of subjects: 144
Study: 31196844

Group type: EXPERIMENTAL
Intervention: TCZ+MTX
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: TCZ
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: TCZ-based strategies
Number of subjects: 426

Group type: COMPARATOR
Intervention: MTX+pred
Number of subjects: 426
Study: 28073779

Group type: EXPERIMENTAL
Intervention: GIP infusion (2 pmol·kg‐1·min‐1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 23
Study: 26721003

Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Delayed Primary Closure (DPC)
Number of subjects: 70
Study: 22332898

Group type: EXPERIMENTAL
Intervention: Routine outcome monitoring (ROM) instruments for mental health assessment
Number of subjects: 1302

Group type: COMPARATOR
Intervention: General population
Number of subjects: 1302
Study: 21079955

Group type: EXPERIMENTAL
Intervention: Topical cyanoacrylate applied every 3 to 5 days for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical silicone gel applied twice a day for 3 months
Number of subjects: 0
Study: 19778479

Group type: EXPERIMENTAL
Intervention: HCG-primed cycles (Group B)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FSH-primed cycles (Group C)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FSH plus HCG-primed cycles (Group D)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-primed cycles (Group A)
Number of subjects: 400
Study: 16824559

Group type: EXPERIMENTAL
Intervention: Bubbles method (revealing small parts of the face)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls (10 individuals)
Number of subjects: 18
Study: 14718419

Group type: EXPERIMENTAL
Intervention: Dry absorbent dressing (Primapore)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Duoderm Thin)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Hydroactive dressing (Opsite)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 737
Study: 12872566

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional laparoscopic approach
Number of subjects: 25
Study: 10197660

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study: 8541635

Group type: EXPERIMENTAL
Intervention: FK506 and prednisolone (FK)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cyclosporine, prednisolone, azathioprine, and rabbit antithymocyte globulin (CsA)
Number of subjects: 121
Study: 2313465

Group type: EXPERIMENTAL
Intervention: ELISA test with monoclonal antibodies against E. histolytica antigen
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard diagnostic methods (OBP and rectosigmoidoscopy)
Number of subjects: 150
Study: 7412226

Group type: EXPERIMENTAL
Intervention: Hearing aids with progressively extended low-frequency emphasis
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hearing aids with low-cutoff frequency settings
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paired-comparison format
Number of subjects: 12
Study: 31496453

Group type: EXPERIMENTAL
Intervention: Digital photographic portion-size estimation aids (PSEA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Actual-food PSEA
Number of subjects: 300

Group type: COMPARATOR
Intervention: Weighed meal record
Number of subjects: 300
Study: 29339527

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone every 2 weeks for 22 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (placebo) every 2 weeks for 22 weeks
Number of subjects: 32
Study: 26901417

Group type: EXPERIMENTAL
Intervention: Geriatric liaison intervention (preoperative consultation, individual treatment plan, daily visits by a geriatric nurse)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Postoperative delirium
Number of subjects: 260
Study: 24476782

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) protocol with traditional strength training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional upper- and lower-body split strength program without BFR
Number of subjects: 62
Study: 22678875

Group type: EXPERIMENTAL
Intervention: Pterygium resection combined with conjunctival autograft
Number of subjects: 118

Group type: COMPARATOR
Intervention: Pterygium resection combined with amniotic membrane transplantation
Number of subjects: 118
Study: 20622670

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Riboflavin 0.1% eyedrops for 1 month of topical use
Number of subjects: 40
Study: 17430602

Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 95
Study: 15936175

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG), mean daily dose of 250 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA), mean daily dose of 2070 mg
Number of subjects: 20
Study: 12085156

Group type: COMPARATOR
Intervention: Risedronate 5 mg once daily
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Risedronate 50 mg once a week
Number of subjects: 1456
Study: 9501262

Group type: EXPERIMENTAL
Intervention: High dose fentanyl anesthesia (50 microg/kg with diazepam 0.1 mg/kg for induction, maintained with fentanyl 2 microg/kg/hr and diazepam 0.05 mg/kg/hr)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone anesthesia (7 mg/kg for induction, maintained with enflurane 0.7‐1.5% and thiopentone 3 mg/kg/hr during CPB)
Number of subjects: 50
Study: 8580271

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s., Metronidazole 400 mg t.d.s. for 14 days
Number of subjects: 119

Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s. and placebo for 14 days
Number of subjects: 119
Study: 29266180

Group type: EXPERIMENTAL
Intervention: 2 ml of 0.4% dexamethasone added to 18 ml 0.5% bupivacaine‐epinephrine
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2 ml 0.9% normal saline added to 18 ml 0.5% bupivacaine‐epinephrine
Number of subjects: 56
Study: 27206636

Group type: EXPERIMENTAL
Intervention: High-volume centers (HVCs)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Low-volume centers (LVCs)
Number of subjects: 495
Study: 25711952

Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx
Number of subjects: 7
Study: 23043368

Group type: EXPERIMENTAL
Intervention: CNTO 5825 (0.1, 0.3, 1.0, 3.0, or 10 mg kg(‐1) i.v. or 3.0 mg kg(‐1) s.c.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CNTO 5825 (10 mg kg(‐1) i.v.) in healthy atopic subjects
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21127156

Group type: EXPERIMENTAL
Intervention: Probiotic E. coli strain Nissle 1917 (Mutaflor), administered at a daily dose of 5×10(9)‐5×10(10) bacteria, twice daily.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 69
Study: 18781073

Group type: EXPERIMENTAL
Intervention: Yacon syrup (20 g daily, equal to 6.4 g FOS)
Number of subjects: 16
Study: 16438769

Group type: EXPERIMENTAL
Intervention: Infero-nasal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Infero-temporal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Number of subjects: 100